Daclatasvir Dihydrochloride
Apejuwe
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) jẹ alagbara ati lọwọ ẹnuHCV NS5A amuaradagbaonidalẹkun pẹluEC50s ibiti o ti 9-146 pM funọpọ HCV ẹda genotypes.Daclatasvir dihydrochloride jẹ tun kanOrganic anion gbigbe polypeptide 1B (OATP1B)atiOATP1B3onidalẹkun pẹluIC50s ti 1.5 µM ati 3.27 µM, lẹsẹsẹ.
IC50& Àkọlé
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) HCV ẹda genotype 5a)[1]
Kd: 8 nM (NS5A33-202) ati 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) ati 3.27 µM (OATP1B3)[3]
Ninu Vitro
Daclatasvir (BMS-790052) ṣe afihan iṣẹ ṣiṣe inhibitory ti o lagbara si gbogbo awọn idanwo genotypes, pẹlu EC50iye orisirisi lati 9 pM to 146 pM.Daclatasvir ṣe idiwọ HCV ẹda genotype 1a, 1b, 2a, 3a, 4a ati 5a pẹlu EC50awọn iye ti 50 pM, 9 pM, 71 pM, 146 pM, 12 pM ati 33 pM, lẹsẹsẹ.Daclatasvir jẹ oludena ti o lagbara ti JFH-1 genotype 2a kokoro àkóràn ti o ṣe atunṣe ni aṣa sẹẹli (EC).50= 28pm)[1].Daclatasvir (BMS-790052) sopọ mọ NS5A33-202 ati NS5A26-202 pẹlu Kds ti 8 nM ati 210 nM, lẹsẹsẹ[2].
Ibi ipamọ
| Lulú | -20°C | 3 odun |
| 4°C | ọdun meji 2 | |
| Ni epo | -80°C | osu 6 |
| -20°C | osu 1 |
Iwadii isẹgun
| Nọmba NCT | Onigbowo | Ipo | Ọjọ Ibẹrẹ | Ipele |
| NCT03369327 | Ile-ẹkọ giga Tehran ti Awọn sáyẹnsì Iṣoogun | Ile-iṣẹ elegbogi RojanPharma | Ikokoro Ẹdọgba C, Idahun si Itọju ti|Kokoro Ajẹsara Ajẹsara Eniyan | Oṣu Kẹta ọjọ 1, Ọdun 2017 | Ipele 3 |
| NCT03485846 | R-Pharm|Almedis | Onibaje Hepatitis C Genotype 1b | Oṣu kọkanla ọjọ 27, Ọdun 2017 | Ipele 2 |
| NCT01016912 | Bristol-Myers Squibb | Ẹdọjẹdọ C Ikolu | Oṣu kejila ọdun 2009 | Ipele 2 |
| NCT01629732 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Kẹta ọdun 2013 | Ipele 2 |
| NCT01497834 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2012 | Ipele 3 |
| NCT01973049 | Bristol-Myers Squibb | Hepatitis C | Oṣu kejila ọdun 2013 | Ipele 3 |
| NCT00663208 | Bristol-Myers Squibb | Hepatitis onibaje C | Oṣu Karun ọdun 2008 | Ipele 2 |
| NCT02576314 | Eda Eniyan ati Ile-iṣẹ Iwadi Ilera | Ile-iwosan Beijing 302 | Onibaje Hepatitis C Ikolu | Oṣu Karun ọdun 2015 | Ipele 3 |
| NCT02756936 | Ile-iṣẹ Iwadi tootọ, Egipti | Awọn ile-iṣẹ elegbogi Zeta Pharma | Ni ilera | Oṣu Kẹta ọdun 2016 | Ipele 1 |
| NCT02771405 | National Hepatology & Ile-iṣẹ Iwadi Oogun Oogun Tropical | Ile-ẹkọ giga Cairo | Ẹdọ̀dọ́ C, Àìrọ́rùn| Ẹjẹ́jẹ̀jẹ̀ Ẹ̀dọ̀kan | Oṣu Kẹta ọdun 2016 | Ipele 3 |
| NCT03706898 | Viriom | HIV-1-infection|Àìlera Ẹdọ̀dọ́ | Oṣu Kẹjọ Ọjọ 1, Ọdun 2018 | Ipele 1 |
| NCT02319031 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2015 | Ipele 3 |
| NCT02124044 | Awọn ile-iṣẹ ti Orilẹ-ede ti Ile-iṣẹ Ilera Ilera (CC)|Ile-ẹkọ ti Orilẹ-ede ti Ẹhun ati Awọn Arun Arun (NIAID) | HIV-HCV | Oṣu Kẹta ọdun 2014 | Ipele 2 |
| NCT02551861 | Bristol-Myers Squibb | Hepatitis C | Oṣu kejila ọdun 2015 | Ipele 2 |
| NCT00859053 | Bristol-Myers Squibb | Ailokun Ẹdọ | Oṣu Kẹta Ọdun 2009 | Ipele 1 |
| NCT01257204 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu kejila ọdun 2010 | Ipele 2 |
| NCT03063879 | Ile-ẹkọ giga Tehran ti Awọn sáyẹnsì Iṣoogun|Ahvaz Jundishapur University of Medical Sciences|Ile-ẹkọ giga Shiraz ti Awọn sáyẹnsì Iṣoogun|Ile-ẹkọ giga Hamadan ti Imọ-iṣe Iṣoogun | Hepatitis C, Chronic|Ikuna Kidirin Onibaje | Oṣu Kẹrin Ọjọ 1, Ọdun 2017 | Ipele 4 |
| NCT01017575 | Bristol-Myers Squibb | Ẹdọjẹdọ C Ikolu | Oṣu kejila ọdun 2009 | Ipele 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Iwosan Severance|Iwosan Yunifasiti Inha| University Korea|Gachon University Gil Medical Centre|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Ile-iwosan University Soonchunhyang | Hepatitis onibaje C | Oṣu Kẹsan 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Hepatitis C, Onibaje | Oṣu Kẹta Ọjọ 29, Ọdun 2019 | Ipele 2 |Ibala 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C | Oṣu Karun ọjọ 18, Ọdun 2018 | Ipele 2 |
| NCT00904059 | Bristol-Myers Squibb | Hepatitis C | Oṣu Karun ọdun 2009 | Ipele 1 |
| NCT02107365 | Ile-ẹkọ Orile-ede Faranse fun Ilera ati Iwadi Iṣoogun-Ile-ibẹwẹ ti Orilẹ-ede Faranse fun Iwadi lori Arun Kogboogun Eedi ati Hepatitis Viral (Inserm-ANRS)|Bristol-Myers Squibb | Ẹdọgba C Iwoye Genotype 4 Ikolu | Oṣu kọkanla ọdun 2013 | Ipele 2 |
| NCT02397395 | Janssen R & D Ireland | Ibanujẹ Kidirin|Ipele Ipari Arun Kidinrin | Oṣu Karun ọdun 2015 | Ipele 2 |
| NCT03169348 | Ile-ẹkọ giga Assiut | Hepatitis C | Oṣu kọkanla ọjọ 1, ọdun 2017 | Ko ṣiṣẹ fun |
| NCT02323594 | Bristol-Myers Squibb | Ẹdọjẹdọ C Ikolu | Oṣu kejila ọdun 2014 | Ipele 1 |
| NCT03537196 | Ile-ẹkọ Orile-ede Faranse fun Ilera ati Iwadi Iṣoogun-Ile-ibẹwẹ ti Orilẹ-ede Faranse fun Iwadi lori Arun Kogboogun Eedi ati Hepatitis Gbogun (Inserm-ANRS) | Ẹdọ̀dọ́ C|Ìlò Oògùn|Ẹ̀dọ̀dọ́ C | Oṣu kọkanla ọjọ 13, Ọdun 2018 | Ipele 4 |
| NCT02103569 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹrin Ọjọ 2014 | Ipele 1 |
| NCT02772744 | Ile-ẹkọ giga Zagazig | Ile-ẹkọ giga Cairo | Hepatitis C | Oṣu kọkanla ọjọ 1, ọdun 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2013 | Ipele 3 |
| NCT02496078 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹjọ Ọdun 2015 | Ipele 3 |
| NCT01425970 | Bristol-Myers Squibb | Hepatitis C | Oṣu Karun ọdun 2012 | Ipele 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | Oṣu kejila ọdun 2011 | Ipele 3 |
| NCT01573351 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Karun ọdun 2012 | Ipele 3 |
| NCT01938625 | Janssen R & D Ireland | Hepatitis C, Onibaje | Oṣu kejila ọjọ 12, Ọdun 2013 | Ipele 2 |
| NCT01492426 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2012 | Ipele 3 |
| NCT03480932 | Ile-iwe Johns Hopkins Bloomberg ti Ilera Awujọ | Ile-ẹkọ ti Orilẹ-ede lori ilokulo Oògùn (NIDA) | Ile-iṣẹ YR Gaitonde fun Iwadi AIDS ati Ẹkọ | Hepatitis C, Onibaje | Oṣu Kẹta Ọjọ 2, Ọdun 2018 | Ipele 2 |Ibala 3 |
| NCT03163849 | Ile-ẹkọ giga Assiut | Ẹdọ̀dọ́ onígboyà c | Oṣu Kẹsan Ọjọ 1, Ọdun 2019 | Ipele 3 |
| NCT01581203 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Karun ọdun 2012 | Ipele 3 |
| NCT01492504 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta Ọjọ 7, Ọdun 2012 |
|
| NCT03686722 | Mohamed Raslan | Ile-ẹkọ giga Ain Shams | Ile-iṣẹ Iwadi Oògùn, Cairo, Egypt | Àtọgbẹ Àtọgbẹ, Iru 2|Hepatitis C|Ìbáṣepọ̀ Oògùn | Oṣu Kẹsan Ọjọ 9, Ọdun 2017 | Ipele 1 |
| NCT02262728 | Janssen Iwadi & Idagbasoke, LLC | Hepatitis C, Onibaje | Oṣu Kẹsan Ọjọ 30, Ọdun 2014 | Ipele 2 |
| NCT02349048 | Janssen Iwadi & Idagbasoke, LLC | Iwoye Ẹdọgba C | Oṣu Kẹta ọdun 2015 | Ipele 2 |
| NCT03882307 | Ile-ẹkọ giga Assiut | Hepatitis C, Onibaje | Oṣu Karun ọdun 2020 | Ipele Ibẹrẹ 1 |
| NCT02758509 | Parc de Salut Mar | Àrùn Ẹdọ̀dọ́ Àbádọ́gba | | Oṣu Kẹta Ọjọ 1, Ọdun 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2013 | Ipele 2 |
| NCT03549832 | Ile-ẹkọ giga Assiut | Ile-ẹkọ giga Sohag | Ile-ẹkọ giga South Valley | HCV Coinfection | Oṣu Kẹta ọjọ 1, Ọdun 2018 | Ko ṣiṣẹ fun |
| NCT02161939 | Bristol-Myers Squibb | Hepatitis onibaje C |
| |
| NCT01309932 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2011 | Ipele 2 |
| NCT01995266 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta Ọjọ 28, Ọdun 2014 | Ipele 3 |
| NCT02640157 | AbbVie | Chronic Hepatitis C|Kọ́rọ̀ Ẹ̀dọ̀dọ́ C | Àrùn Ẹ̀dọ̀ Àrùn 3 | Oṣu kejila ọdun 2015 | Ipele 3 |
| NCT02032875 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2014 | Ipele 3 |
| NCT02624063 | Federal University of São Paulo | Hepatitis C, Onibaje | Oṣu kejila ọdun 2015 | Ipele 4 |
| NCT00546715 | Bristol-Myers Squibb | Hepatitis onibaje C | Oṣu kọkanla ọdun 2007 | Ipele 1 |Ibala 2 |
| NCT01718145 | Bristol-Myers Squibb | Ikolu Ẹdọgba C | Oṣu kọkanla ọdun 2012 | Ipele 3 |
| NCT01616524 | Bristol-Myers Squibb | Kokoro Hepatitis C (HCV) | Oṣu Keje ọdun 2012 | Ipele 3 |
| NCT02032901 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2014 | Ipele 3 |
| NCT03540212 | Ile-ẹkọ giga Ain Shams | Onibaje HCV Ikolu | Oṣu kejila ọjọ 10, Ọdun 2017 | Ipele 2 |Ibala 3 |
| NCT02097966 | Bristol-Myers Squibb | Hepatitis onibaje C |
| |
| NCT02596880 | Tehran University of Medical Sciences | Ẹdọ̀dọ̀dọ̀ C | Cirrhosis | Oṣu Kẹsan 2015 | Ipele 3 |
| NCT04019717 | Atea Pharmaceuticals, Inc. | Ẹdọ̀dọ́ C|Ẹ̀dọ̀dọ́ C, Àìlera | Oṣu Kẹfa Ọjọ 20, Ọdun 2019 | Ipele 2 |
| NCT02992457 | Ile-ẹkọ giga Tanta | Hepatitis C | Oṣu Kẹta ọdun 2015 | Ipele 4 |
| NCT03547895 | Ile-ẹkọ giga Zagazig | Cirrhosis ti a ti bajẹ | Oṣu Kẹfa Ọjọ 1, Ọdun 2015 | Ko ṣiṣẹ fun |
| NCT03004625 | Ile-iwosan Iṣoogun ti Kaohsiung Chung-Ho | Ile-iwosan Iranti Chang Gung | Ile-iwosan Ile-ẹkọ giga ti Orilẹ-ede Taiwan | Ile-iwosan Gbogbogbo ti Taipei Veterans, Taiwan | Ile-iwosan Iṣoogun ti Ilu China | Ile-iwosan Ile-ẹkọ giga ti Orilẹ-ede Cheng-Kung | Hepatitis C | Oṣu kọkanla ọdun 2016 | Ipele 3 |
| NCT01051414 | Bristol-Myers Squibb | Ẹdọjẹdọ C Ikolu | Oṣu Kẹrin Ọjọ 2010 | Ipele 2 |
| NCT02309450 | Ile-ẹkọ Orile-ede Faranse fun Ilera ati Iwadi Iṣoogun-Ile-ibẹwẹ ti Orilẹ-ede Faranse fun Iwadi lori Arun Kogboogun Eedi ati Hepatitis Viral (Inserm-ANRS)|Bristol-Myers Squibb | Ẹdọgba C Iwoye Genotype 4 Ikolu | Oṣu kejila ọdun 2014 | Ipele 2 |
| NCT01628692 | Bristol-Myers Squibb | Iwadi Janssen & Idagbasoke, LLC | Iwoye Ẹdọgba C | Oṣu Keje ọdun 2012 | Ipele 2 |
| NCT03186313 | Ile-iwosan Ẹdọ ara Egipti | Ile-iwosan Wadi El Nil | Hepatitis C | Oṣu Kẹsan 2016 | Ipele 3 |
| NCT03063723 | Ile-iwosan Alafaramo Kẹta, Ile-ẹkọ giga Sun Yat-Sen | Hepatitis C onibaje (Ibajẹ) | Oṣu Kẹta ọjọ 1, Ọdun 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Hepatitis onibaje C | Oṣu Kẹwa Ọdun 2009 | Ipele 1 |
| NCT01725542 | Ile-ẹkọ Orile-ede Faranse fun Ilera ati Iwadi Iṣoogun-Ile-ibẹwẹ ti Orilẹ-ede Faranse fun Iwadi lori Arun Kogboogun Eedi ati Hepatitis Viral (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Co-ikolu | Oṣu kejila ọdun 2012 | Ipele 2 |
| NCT02282709 | Ipilẹ fun Iwadi Ẹdọ | Hepatitis onibaje C | Oṣu Kẹta ọdun 2014 | Ipele 3 |
| NCT02032888 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹta ọdun 2014 | Ipele 3 |
| NCT03247296 | Ile-ẹkọ giga MTI | Hepatitis C | Oṣu Kẹta Ọjọ 28, Ọdun 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹsan 2011 | Ipele 3 |
| NCT02556086 | Bristol-Myers Squibb | Hepatitis C | Oṣu kejila ọdun 2015 | Ipele 2 |
| NCT01741545 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Kẹta Ọjọ 31, Ọdun 2013 | Ipele 3 |
| NCT01866930 | Bristol-Myers Squibb | Onibaje Hepatitis C Ikolu | Oṣu Keje 11, Ọdun 2013 | Ipele 3 |
| NCT02268864 | Janssen-Cilag International NV | Hepatitis C, Onibaje | Oṣu Kẹta ọdun 2015 | Ipele 2 |
| NCT01797848 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹfa ọdun 2014 | Ipele 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah | Ile-ẹkọ giga Assiut | Hepatitis C | Oṣu Kẹfa ọdun 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹfa ọdun 2014 | Ipele 1 |
| NCT01125189 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Keje Ọdun 2010 | Ipele 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Oògùn Awọn ibaraẹnisọrọ | Oṣu kọkanla ọjọ 19, Ọdun 2018 | Ipele 1 |
| NCT01012895 | Bristol-Myers Squibb | Hepatitis onibaje C | Oṣu kejila ọdun 2009 | Ipele 2 |
| NCT02565888 | Ile-ẹkọ giga Radboud | Hepatitis C|HIV | Oṣu kọkanla ọdun 2015 | Ipele 1 |
| NCT02555943 | Eda Eniyan ati Ile-iṣẹ Iwadi Ilera | Ile-iwosan Beijing 302 | Ile-iwosan Nanfang ti Ile-ẹkọ giga Iṣoogun Gusu | Àkóràn Ẹdọ̀dọ́ C Chronic|HBV Coinfection|Àtúnṣe Ẹdọ̀dọ́ B | Oṣu Kẹta ọdun 2015 | Ipele 2 |Ibala 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Ile-iṣẹ Iwadi Gusu California | Ẹdọ̀dọ̀dọ̀ C | Cirrhosis | Oṣu Kẹta ọdun 2015 | Ipele 4 |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Iwosan Ile-ẹkọ giga Soonchunhyang | Ile-ẹkọ giga Dankook | Ile-iwosan Ile-ẹkọ giga ti Orilẹ-ede Chungnam | Ile-iwosan Yunifasiti ti Konyang | Ile-iwosan Yunifasiti Eulji | Ile-iwosan Saint Vincent's, Korea | Ile-iwosan University Konkuk | Ile-iwosan Cheongju St. Mary’s, Cheongju , Korea|Ile ìwòsàn Severance|Ile ìwòsàn Yunifásítì Korea|Ile ìwòsàn Gbogbogbò Eulji|Ile-ẹkọ giga Katoliki ti Korea | Hepatitis C | Oṣu Kẹta ọdun 2016 | Ipele 4 |
| NCT02104843 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹrin Ọjọ 2014 | Ipele 1 |
| NCT01428063 | Bristol-Myers Squibb | Ikolu Ẹdọgba C | Oṣu Kẹsan 2011 | Ipele 2 |
| NCT02123654 | Bristol-Myers Squibb | Ikolu Ẹdọgba C | Oṣu Kẹrin Ọjọ 2014 | Ipele 3 |
| NCT02565862 | Ile-ẹkọ giga Radboud | Hepatitis C| Àtọgbẹ Àtọgbẹ|Ìforíkorí insulin | Oṣu Kẹta ọdun 2016 | Ipele 1 |
| NCT04211844 | Ile-ẹkọ giga Ain Shams | Hepatitis onibaje C | Oṣu Kẹjọ Ọjọ 1, Ọdun 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Ẹdọjẹdọ C Ikolu | Oṣu Kẹfa ọdun 2009 | Ipele 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Ikuna Kidney, Chronic|Hepatitis C | Oṣu Kẹta Ọjọ 15, Ọdun 2019 | Ipele 3 |
| NCT01448044 | Bristol-Myers Squibb | Hepatitis C | Oṣu kejila ọdun 2011 | Ipele 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Hepatitis onibaje C | Oṣu Kẹfa ọdun 2011 | Ipele 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | Àbádọ̀dọ́-arun C|CHC|HCV|Ẹ̀dọ̀dọ́ C | Oṣu Kẹfa ọdun 2013 | Ipele 2 |
| NCT02762448 | Tainan Municipal Hospital | Hepatitis c | Oṣu Keje ọdun 2016 |
|
| NCT02473211 | Eda Eniyan ati Ile-iṣẹ Iwadi Ilera | Ile-iwosan Beijing 302 | Onibaje Hepatitis C Ikolu | Oṣu Kẹta ọdun 2015 | Ipele 2 |Ibala 3 |
| NCT01455090 | Bristol-Myers Squibb | Hepatitis onibaje C | Oṣu kọkanla ọjọ 30, Ọdun 2011 | Ipele 2 |
| NCT03490097 | Ile-ẹkọ giga Ain Shams | Hepatitis Onibaje c|Aisan ti iṣelọpọ agbara | Oṣu kejila ọjọ 1, ọdun 2017 | Ipele 2 |Ibala 3 |
| NCT01170962 | Bristol-Myers Squibb | Iwoye Ẹdọgba C | Oṣu Kẹjọ Ọdun 2010 | Ipele 2 |
| NCT02333292 | Ile-iwosan Ile-ẹkọ giga Valme | Ile-iwosan del SAS de Jerez | Ile-iwosan Gbogbogbo Universitario Elche | Ile-iwosan La Línea de la Concepción | Complexo Hospitalario Universitario de A Coruña | Ile-iwosan de Figueres | Ile-iwosan Universitario Puerto Real | Ile-iwosan Universitario Virgen de la Victoria |Hospital Universitario Virgen de la Victoria Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Ile iwosan Universitario Virgen Macarena|Ile iwosan Universitario Virgen Macarena|Complexolin University of Burgos Navarra | Ile-iwosan Ile-iwosan Universitario San Cecilio | Ile-iwosan Universitario La Fe | Ile-iwosan Gbogbogbo Universitario de Valencia | Ile-iwosan Universitario Infanta Leonor la Luz|Ile ìwòsàn Gbogbogbo Universitario de Castellón|Ile ìwòsàn Parc Taulí, Sabadell | Onibaje Hepatitis C Ikolu | Oṣu kejila ọdun 2014 |
|
| NCT03200184 | Tehran University of Medical Sciences | Hepatitis C | Oṣu Kẹsan Ọjọ 1, Ọdun 2016 | Ipele 4 |
| NCT03188276 | Ile-iwosan Alafaramo Kẹta, Ile-ẹkọ giga Sun Yat-Sen | Hepatitis onibaje C | Oṣu Kẹta Ọjọ 1, Ọdun 2016 | Ipele Ibẹrẹ 1 |
| NCT01830205 | Bristol-Myers Squibb | Hepatitis C | Oṣu Kẹsan 2012 | Ipele 1 |
Igbero18Awọn iṣẹ akanṣe Igbelewọn Iṣeduro Didara eyiti o ti fọwọsi4, ati6ise agbese ni o wa labẹ alakosile.
Eto iṣakoso didara agbaye ti ilọsiwaju ti fi ipilẹ to lagbara fun tita.
Abojuto didara n ṣiṣẹ nipasẹ gbogbo igbesi aye ọja lati rii daju didara ati ipa itọju ailera.
Ẹgbẹ Aṣoju Iṣeduro Ọjọgbọn ṣe atilẹyin awọn ibeere didara lakoko ohun elo ati iforukọsilẹ.
Koria Countec Bottled Packaging Line
Taiwan CVC Laini Iṣakojọpọ Igo
Italy CAM Board Packaging Line
German Fette Compacting Machine
Japan Viswill Tablet Oluwari
DCS Iṣakoso yara
International ifowosowopo
Abele ifowosowopo
Kọ ifiranṣẹ rẹ nibi ki o si fi si wa
